Unique ID issued by UMIN | UMIN000004398 |
---|---|
Receipt number | R000005259 |
Scientific Title | Open label randomized trial of treatment by perospirone and aripiprazole for schizophrenia patients considering the drug susceptibility gene |
Date of disclosure of the study information | 2010/10/22 |
Last modified on | 2017/10/23 10:59:42 |
Open label randomized trial of treatment by perospirone and aripiprazole for schizophrenia patients considering the drug susceptibility gene
Controlled clinical comparison of perospirone and aripiprazole considering the drug susceptibility gene
Open label randomized trial of treatment by perospirone and aripiprazole for schizophrenia patients considering the drug susceptibility gene
Controlled clinical comparison of perospirone and aripiprazole considering the drug susceptibility gene
Japan |
Schizophrenia
Psychiatry |
Others
YES
To compare the therapeutic efficacy and tolerability of perospirone and aripiprazole in patients with schizophrenia considering the drug susceptibility gene.
PK,PD
Exploratory
Explanatory
Not applicable
Positive and Negative Syndrome Scale
Gene polymorphism
Drug-Induced Extrapyramidal Symptoms Scale
Barnes Akathisia Scale
Clinical Global Impression
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Uncontrolled
NO
NO
Institution is not considered as adjustment factor.
NO
Numbered container method
2
Treatment
Medicine |
Perospirone
Aripiprazole
15 | years-old | < |
Not applicable |
Male and Female
Patients (inpatients and outpatients) over 15 years of age, who were diagnosed with schizophrenia (according to the DSM-IV criteria) and were required to have scores PANSS total score 60 or more, and a score 4 or more on at least two of the PANSS-positive items assessing delusions, hallucinatory behavior or conceptual disorganization, were eligible. Patients for whom the total dose of antipsychotics (haloperidol equivalent dose) is lower than 12.0 mg/day at screening.
Patient with coma; under the depressant by barbiturates, received perospirone or aripiprazole within 4 weeks (30 days), participated in a clinical study or post-marketing clinical study within 12 months (180 days), were pregnant or may become pregnant or nursing, history of drug and alcohol abuse, neuroleptic malignant syndrome, water intoxication, known hypersensitivity to study drugs, significant risk of suicide, currently epinephrine administration precluded entry into the study, and patients considered as inadequate by investigator.
100
1st name | |
Middle name | |
Last name | Yoshiteru Takekita |
Kansai Medical University
Department of Neuropsychiatry
10-15 fumizono-cho, Moriguchi Osaka, 570-8506, Japan
06-6992-1001
takekity@takii.kmu.ac.jp
1st name | |
Middle name | |
Last name | Yoshiteru Takekita |
Kansai Medical University
Department of Neuropsychiatry
10-15 fumizono-cho, Moriguchi Osaka, 570-8506, Japan
06-6992-1001
takekity@takii.kmu.ac.jp
Department of Neuropsychiatry, Kansai Medical University
Japan Society for the Promotion of Science
Dainippon Sumitomo Pharma Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.
Other
Japan
Hyogo University of Health Sciences
NO
関西医科大学附属滝井病院(大阪府)
2010 | Year | 10 | Month | 22 | Day |
Unpublished
Open public recruiting
2009 | Year | 12 | Month | 05 | Day |
2010 | Year | 03 | Month | 01 | Day |
2012 | Year | 03 | Month | 01 | Day |
2012 | Year | 04 | Month | 01 | Day |
2012 | Year | 12 | Month | 01 | Day |
2010 | Year | 10 | Month | 18 | Day |
2017 | Year | 10 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005259
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |